光动力疗法联合Lucentis玻璃体腔注射治疗CNV的疗效观察

Clinical observation of photodynamic therapy combined with vitreous cavity injection of Lucentis treatment for choroidal neovascularization diseases

目的：观察光动力疗法（PDT）联合Lucentis玻璃体腔注射治疗脉络膜新生血管疾病（CNV）的近期疗效和安全性。方法对30例（30只眼）经眼压、眼底检查、荧光素眼底血管造影（FFA）以及光学相干断层扫描（OCT）等检查确诊为CNV患者行PDT联合Lucentis玻璃体腔注射治疗的患者资料进行回顾性分析。结果经4-6个月随访，30只眼中有22只眼视力提高（占73．3％），8只眼视力稳定（占26．7％），未见有视力下降者。20例AMD患者中14例（70．0％）通过一次联合治疗后CNV消退；3例（15．0％）3个月后需再次Lucentis玻璃体腔注射治疗。10例特发性脉络膜新生血管病例通过一次联合治疗而使CNV消退。治疗及随访期间无全身和眼部并发症发生。结论PDT联合Lucentis玻璃体腔注射治疗CNV的疗效显著，可以提高患者视力及减少重复治疗的次数。

Objective To investigate the efficacy and safety of photodynamic therapy（PDT） combined with vitreous cavity injec‐tion of Lucentis treatment for choroidal neovascularization（CNV） diseases .Methods we retrospectively analyzed data of 30 cases （30 eyes） of CNV ,who was diagnosed by examination of visual acuity ,intmocular pressure ,ocular fundus ,fundus fluorescein angi‐ography （FFA） ,and optic coherence tomography（OCT） ,and who underwent PDT combined with intravitreal injection of Lucentis . Results At the 4 - 6 months follow‐up ,the best corrected visual acuity（BCVA） improved in 22 eyes（73 .3% ） ,stabilized in 8 eyes （26 .7% ） and none decreased .Among the AMD ,14 cases（70 .0% ） required only a single combined treatment for CNV resolution ;3 cases of AMD needed retreatment 3 months later .In CNV group ,all of the cases required only a single combined treatment for CNV resolution .At the therapy and follow‐up period ,no ocular or systemic adverse reactions were noted .Conclusion The treatment of PDT combine intravitreal injection of Lucentis is safe and effective for CNV ,which could improve visual acuity and reduce retreat‐ment rates .